Related Experiment Videos
Analgesic treatment in acute myocardial infarction: a comparison between indoprofen and morphine by a double-blind
Abstract:
On the basis of the results of an earlier study, showing that i.v. indoprofen induced no clinically significant changes in hemodynamic parameters of patients with acute myocardial infarction (AMI), a double-blind randomized trial was carried out in 40 AMI patients to evaluate the analgesic activity of 400 mg i.v. indoprofen in comparison with 10 mg i.m. morphine hydrochloride. Pain severity was recorded before and at several intervals within 24 h after drug administration. The average analgesic response was prompt and progressive up to the 6th hour in both treatment groups, with no significant difference between drugs in various pain descriptors. However, the proportion of responding patients in indoprofen group was greater than in morphine group at all observation times, indicating a significant difference (p less than 0.05) in favor of indoprofen. In view of its good tolerability, i.v. indoprofen is worth considering in early AMI as an alternative to morphine in those patients in whom non-opiate analgesia might be preferable.
Insights
Intravenous indoprofen effectively relieved pain in acute myocardial infarction (AMI) patients, showing a greater patient response rate than morphine. This non-opiate option offers good tolerability for AMI pain management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Intravenous indoprofen demonstrated no significant hemodynamic changes in acute myocardial infarction (AMI) patients in prior research.
- Effective pain management is crucial in the early stages of AMI.
Purpose of the Study:
- To compare the analgesic efficacy of intravenous indoprofen versus intramuscular morphine in patients with AMI.
- To evaluate pain severity and patient response over 24 hours post-administration.
Main Methods:
- A double-blind, randomized trial involving 40 AMI patients.
- Administration of 400 mg i.v. indoprofen or 10 mg i.m. morphine hydrochloride.
- Pain severity assessment at multiple intervals within 24 hours.
Main Results:
- Both indoprofen and morphine provided prompt and progressive analgesia up to 6 hours.
- No significant differences were observed in pain descriptor responses between the two drugs.
- A significantly higher proportion of patients responded to indoprofen compared to morphine (p < 0.05).
Conclusions:
- Intravenous indoprofen exhibits favorable analgesic properties in early AMI.
- Indoprofen demonstrates good tolerability, making it a potential alternative to morphine for non-opiate analgesia in AMI.
- Further consideration of i.v. indoprofen is warranted for AMI pain management.